BMY Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 3/6 |
Dividends | 5/6 |
Bristol-Myers Squibb Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$49.02 |
52 Week High | US$81.44 |
52 Week Low | US$48.42 |
Beta | 0.37 |
1 Month Change | -3.92% |
3 Month Change | -22.00% |
1 Year Change | -38.06% |
3 Year Change | -21.44% |
5 Year Change | -8.00% |
Change since IPO | 244.00% |
Recent News & Updates
Bristol-Myers Squibb: The Patent Expiry Challenge
Nov 23Bristol Myers Squibb: Bright Future Ahead
Nov 17Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Nov 08Recent updates
Bristol-Myers Squibb: The Patent Expiry Challenge
Nov 23Bristol Myers Squibb: Bright Future Ahead
Nov 17Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Nov 08Bristol-Myers Squibb: Time To Get Greedy
Oct 21Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud
Oct 09Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years
Sep 26Bristol Myers Squibb: Pharma And Government Playing 'Chicken' Over New Drug Pricing Rules
Sep 16Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Might Deserve Your Attention Today
Sep 09Bristol-Myers Squibb: Patents, Profits, And Prognosis
Aug 24Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly
Aug 01Bristol-Myers: Potentially Set To Soar And Too Cheap To Ignore
Jul 19Bristol-Myers Squibb: Back In The Doldrums - Or Just Pausing For Breath?
Jul 06Bristol Myers Squibb: Take The Red Pill
Jun 05High Quality Dividend Growth Near 52-Week Lows: Bristol-Myers Squibb Is A Good Bet
May 30Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Might Deserve Your Attention Today
May 21Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Apr 27Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.57
Apr 05Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.57
Mar 09Bristol's Opdivo improves disease-free survival in urothelial carcinoma over long term
Feb 17Shareholder Returns
BMY | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 0.2% | -0.1% | 0.1% |
1Y | -38.1% | -3.1% | 13.5% |
Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned -3.1% over the past year.
Return vs Market: BMY underperformed the US Market which returned 13.5% over the past year.
Price Volatility
BMY volatility | |
---|---|
BMY Average Weekly Movement | 3.3% |
Pharmaceuticals Industry Average Movement | 10.4% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 15.4% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BMY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BMY's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1887 | 34,300 | Chris Boerner | https://www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company Fundamentals Summary
BMY fundamental statistics | |
---|---|
Market Cap | US$101.25b |
Earnings (TTM) | US$8.29b |
Revenue (TTM) | US$44.94b |
12.0x
P/E Ratio2.2x
P/S RatioIs BMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BMY income statement (TTM) | |
---|---|
Revenue | US$44.94b |
Cost of Revenue | US$10.33b |
Gross Profit | US$34.60b |
Other Expenses | US$26.32b |
Earnings | US$8.29b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 02, 2024
Earnings per share (EPS) | 4.07 |
Gross Margin | 77.01% |
Net Profit Margin | 18.44% |
Debt/Equity Ratio | 129.6% |
How did BMY perform over the long term?
See historical performance and comparison